S
Scott R. Plotkin
Researcher at Harvard University
Publications - 231
Citations - 11519
Scott R. Plotkin is an academic researcher from Harvard University. The author has contributed to research in topics: Neurofibromatosis & Schwannomatosis. The author has an hindex of 48, co-authored 202 publications receiving 10000 citations. Previous affiliations of Scott R. Plotkin include Brigham and Women's Hospital & Duke University.
Papers
More filters
Journal ArticleDOI
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Tracy T. Batchelor,A. Gregory Sorensen,A. Gregory Sorensen,Emmanuelle di Tomaso,Wei Ting Zhang,Wei Ting Zhang,Dan G. Duda,Kenneth S. Cohen,Kevin R. Kozak,Daniel P. Cahill,Poe Jou Chen,Poe Jou Chen,Mingwang Zhu,Mingwang Zhu,Marek Ancukiewicz,Maciej M. Mrugala,Scott R. Plotkin,Jan Drappatz,David N. Louis,Percy Ivy,David T. Scadden,Thomas Benner,Jay S. Loeffler,Patrick Y. Wen,Rakesh K. Jain +24 more
TL;DR: This study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.
Journal ArticleDOI
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor,Dan G. Duda,Emmanuelle di Tomaso,Marek Ancukiewicz,Scott R. Plotkin,Elizabeth R. Gerstner,April F. Eichler,Jan Drappatz,Fred H. Hochberg,Thomas Benner,David N. Louis,Kenneth S. Cohen,Houng Chea,Alexis Exarhopoulos,Jay S. Loeffler,Marsha A. Moses,Percy Ivy,A. Gregory Sorensen,Patrick Y. Wen,Rakesh K. Jain +19 more
TL;DR: Cediranib monotherapy for recurrent glioblastoma is associated with encouraging proportions of radiographic response, 6-month progression-free survival, and a steroid-sparing effect with manageable toxicity.
Journal ArticleDOI
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon,Karen Fink,Tom Mikkelsen,Timothy F. Cloughesy,Alison M. O'Neill,Scott R. Plotkin,Michael Glantz,Paula Ravin,Jeffrey J. Raizer,Keith M. Rich,David Schiff,William R. Shapiro,Susan Burdette-Radoux,Edward J. Dropcho,Sabine M. Wittemer,Johannes Nippgen,Martin Picard,L. Burt Nabors +17 more
TL;DR: Cilengitide monotherapy is well tolerated and exhibits modest antitumor activity among recurrent GBM patients, and additional studies integrating cilENGitide into combinatorial regimens for GBM are warranted.
Journal Article
Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism.
TL;DR: It is shown thatRadioiodinated murine IL-1 beta and especially murineIL-1 alpha are even more rapidly transported into the brain of the mouse than is radioiodinated human IL- 1 alpha after i.v. injection, showing that there are not three separate transport systems, but that they either share transport systems with overlapping affinities or share a single system.
Journal ArticleDOI
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Scott R. Plotkin,Anat Stemmer-Rachamimov,Fred G. Barker,Chris Halpin,Timothy P. Padera,Alex Tyrrell,A. Gregory Sorensen,Rakesh K. Jain +7 more
TL;DR: VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas.